Clavé Biodesign develops a unique and transformative technology that targets circulating bone marrow derived cells as a natural delivery mechanism for imaging and therapeutic agents for the treatment of cancer. Clavé’s innovative technology overcomes the shortcomings of other tumor vascular targeting methods by avoiding toxicities that are typically associated with previous targeting approaches.

The ability to characterize distinct cellular features of tumor vasculature noninvasively using this innovative technologic platform will further oncology care by enabling personalized approaches. There is a substantial commercial opportunity for this disruptive approach with potential downstream cost savings through earlier and more precise diagnosis and treatment.